HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo.

Abstract
Complement plays a role in activating the inflammatory response and has been implicated in the pathogenesis of some inflammatory diseases. With a view toward controlling unwanted C activation, we evaluated the C regulator, human decay accelerating factor (DAF). Three forms of recombinant DAF were purified from transfected Chinese hamster ovary cells: glycophosphatidylinositol (GPI)-linked membrane DAF (mDAF) extracted from cell membranes; spontaneously shed soluble DAF (sDAF) derived from mDAF; and a novel secreted protein (seDAF), generated by deletion of the signal for GPI attachment. We show that all three molecules inhibit both the classical and alternative pathways of C activation. The following observations indicate that mDAF extracted from Chinese hamster ovary cells reincorporates into RBC membranes via its GPI anchor: 1) cells that are preincubated with mDAF and then washed remain fully protected from C-mediated hemolysis; 2) incubation with phosphatidylinositol-specific phospholipase C abolishes this protection; and 3) sDAF and seDAF, which lack a GPI anchor, do not associate with cell membranes. mDAF is a more potent inhibitor of C-mediated hemolysis than either sDAF or seDAF, suggesting that incorporation into cell membranes greatly enhances the efficiency with which DAF inhibits C activation on the cell surface. In contrast, C activation in the fluid phase is inhibited by sDAF and seDAF, but not by mDAF, possibly due to interference by serum lipoproteins. A reversed passive Arthus reaction in guinea pigs was used to evaluate the ability of recombinant seDAF to inhibit C activation in vivo. When administered at dermal sites, seDAF reduced the severity of immune complex-mediated inflammatory reactions induced by a reversed passive Arthus reaction, as judged by both gross and histologic examination. These data indicate that seDAF may be useful as an anti-inflammatory therapeutic.
AuthorsP Moran, H Beasley, A Gorrell, E Martin, P Gribling, H Fuchs, N Gillett, L E Burton, I W Caras
JournalJournal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 149 Issue 5 Pg. 1736-43 (Sep 01 1992) ISSN: 0022-1767 [Print] United States
PMID1380537 (Publication Type: Journal Article)
Chemical References
  • CD55 Antigens
  • Complement Inactivator Proteins
  • Membrane Proteins
  • Recombinant Proteins
Topics
  • Animals
  • Arthus Reaction (prevention & control)
  • Base Sequence
  • CD55 Antigens
  • Complement Activation (drug effects)
  • Complement Inactivator Proteins (pharmacology)
  • Guinea Pigs
  • Humans
  • In Vitro Techniques
  • Membrane Proteins (pharmacology)
  • Mice
  • Molecular Sequence Data
  • Rabbits
  • Rats
  • Recombinant Proteins (pharmacology)
  • Species Specificity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: